GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 172 FORM NO. AOC.2 (Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014) Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm’s length transactions under third proviso thereto 1. Details of contracts or arrangements or transactions not at arm’s length basis: NA (a) Name(s) of the related party and nature of relationship (b) Nature of contracts/arrangements/transactions (c) Duration of the contracts/arrangements/transactions (d) Salient terms of the contracts or arrangements or transactions including the value, if any (e) Justification for entering into such contracts or arrangements or transactions (f) Date of approval by the Board (g) Amount paid as advances, if any (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188 2. Details of material contracts or arrangements or transactions at arm’s length basis (a) Name(s) of the related party and nature of relationship – GlaxoSmithKline Asia Private Limited, a Promoter Group Company. (b) Nature of contracts/arrangements/transactions – Transfer of trademarks pertaining to Iodex and Ostocalcium Brands and other identified assets. (c) Duration of the contracts/arrangements/transactions – Transaction concluded during the year. (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Total transaction value of ` 1649,01.00 lakhs. (e) Date(s) of approval by the Board, if any: 26 July 2021 (f) Amount paid as advances, if any: NA On behalf of the Board of Directors Ms. R. S. Karnad Mumbai, 16 May, 2022 Chairperson